Fernanda Cristina dos Santos Simão

Fernanda Cristina dos Santos Simão

Auto-generated profile, based on publicly available information

Fernanda Cristina dos Santos Simão

Associação Brasileira de Talassemia - Abrasta. São Paulo, SP, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2026 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
JGJanaína Rosenburg Gioseffi
Janaína Rosenburg Gioseffi
FSFernanda Cristina dos Santos Simão
Fernanda Cristina dos Santos Simão
NMNina Melo
Nina Melo
EFEduardo Maercio Fróes
Eduardo Maercio Fróes
TATalita Garrido Araújo
Talita Garrido Araújo
SLSandra Loggetto
Sandra Loggetto
To outline the sociodemographic and therapeutic profile of individuals with thalassemia in Brazil between 2012 and 2022, by analyzing data from the Ministry of Health on outpatient care, hospitalization, and mortality records. This descriptive, cross-sectional study utilized secondary data from the Outpatient, Hospital, and Mortality Information Systems of the Ministry of Health on patients diagnosed with thalassemia (ICD-10 D56). Analyzed variables included demographics (sex, age, race/ethnicity), geographic location (residence and treatment site), and clinical outcomes (procedures, hospitalizations, and deaths). In 2022, an estimated 662 patients received outpatient treatment in the Brazilian Unified Health System (SUS), with a predominance of young adults, women, and individuals self-identified as White, who were mostly concentrated in the southeastern and southern regions of the country. Red blood cell transfusion was the most frequently performed outpatient procedure during the period. There were 1278 hospitalizations, mainly of children aged 0-9 years. A total of 153 deaths were recorded, primarily among people aged 50 years or older. The findings characterize the patient profile, identify significant travel challenges to receive treatment, and suggest potential underreporting within reference institutions. It is essential to improve data recording in public databases to support specific health policies and ensure comprehensive, equitable, and continuous treatment for people living with thalassemia in Brazil.

20 May 2025 in Saúde Coletiva (Barueri)
Verified
Journal Article
Open access
PDF file
ASAna Carolina Gomes dos Santos
Ana Carolina Gomes dos Santos
AAAna Beatriz Machado de Almeida
Ana Beatriz Machado de Almeida
FSFernanda Cristina Santos Simão
Fernanda Cristina Santos Simão
NMNina Melo
Nina Melo
JGJanaína Rosenburg Gioseffi
Janaína Rosenburg Gioseffi
NHNelson Hamerschlak
Nelson Hamerschlak
OBJETIVO: Este estudo analisou dados sociodemográficos e o tratamento de pacientes portadores de mieloma múltiplo no Brasil, identificando impactos nos sistemas de saúde. MÉTODOS: Estudo descritivo por meio de questionário autopreenchido, enviado entre outubro de 2021 e janeiro de 2023 a pacientes cadastrados na Associação Brasileira de Linfoma e Leucemia (Abrale). RESULTADOS: Participaram 164 pacientes, dos quais 133 (81%) tinham sintomas antes do diagnóstico. A maioria (117; 71%) passou por duas ou mais consultas antes do hematologista. O tempo médio para diagnóstico foi maior no sistema público (178 dias) que no privado (128 dias), e 38% relataram dificuldades de acesso. O diagnóstico e tratamento impactaram a rotina de 138 (84%) pacientes. CONCLUSÃO: Os resultados reforçam a importância de mapear obstáculos para discutir melhorias no tratamento e garantir atendimento adequado a todos.